Estrella Immunopharma Files 2024 Annual Report

Ticker: ESLAW · Form: 10-K · Filed: Sep 27, 2024 · CIK: 1844417

Sentiment: neutral

Topics: annual-report, biotech, sec-filing

TL;DR

Estrella Immunopharma filed its 10-K for FY24. Check financials.

AI Summary

Estrella Immunopharma, Inc. filed its annual report for the fiscal year ended June 30, 2024. The company, formerly known as TradeUP Acquisition Corp., is focused on biological products. Its principal executive offices are located at 5858 Horton Street, Suite 370, Emeryville, California.

Why It Matters

This filing provides a comprehensive overview of Estrella Immunopharma's financial performance and business operations for the past fiscal year, which is crucial for investors and stakeholders to assess the company's current standing and future prospects.

Risk Assessment

Risk Level: low — This is a standard annual report filing and does not contain immediate, high-impact news or disclosures.

Key Numbers

Key Players & Entities

FAQ

What is Estrella Immunopharma's primary business focus?

Estrella Immunopharma, Inc. is focused on biological products, as indicated by its Standard Industrial Classification code [2836].

When did Estrella Immunopharma change its name from TradeUP Acquisition Corp.?

The filing indicates the former company name was TradeUP Acquisition Corp. and the date of name change was 20210204.

Where are Estrella Immunopharma's principal executive offices located?

The principal executive offices are located at 5858 Horton Street, Suite 370, Emeryville, California, 94608.

What is the SEC file number for Estrella Immunopharma?

The SEC file number for Estrella Immunopharma, Inc. is 001-40608.

For which fiscal year is this 10-K report filed?

This 10-K report is filed for the fiscal year ended June 30, 2024.

Filing Stats: 4,404 words · 18 min read · ~15 pages · Grade level 16 · Accepted 2024-09-26 19:50:52

Key Financial Figures

Filing Documents

Business

Item 1. Business 1 Item 1A. Risk Factors 55 Item 1B. Unresolved Staff Comments 122 Item 1C. Cybersecurity 123 Item 2. Properties 123 Item 3. Legal Proceedings 123 Item 4. Mine Safety Disclosures 123 PART II 124 Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 124 Item 6. [Reserved] 127 Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 128 Item 7A. Quantitative and Qualitative Disclosures About Market Risk 137 Item 8. Financial Statements and Supplementary Data 137 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 137 Item 9A. Controls and Procedures 137 Item 9B. Other Information 138 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 138 PART III 139 Item 10. Directors, Executive Officers and Corporate Governance 139

Executive Compensation

Item 11. Executive Compensation 139

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 139

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence 139

Principal Accounting Fees and Services

Item 14. Principal Accounting Fees and Services 139 PART IV 140 Item 15. Exhibits, Financial Statement Schedules 140 Item 16. Form 10-K Summary 144 i Estrella MARKET AND INDUSTRY DATA This Annual Report includes estimates regarding market and industry data and forecasts, which are based on our own estimates utilizing our management's knowledge of and experience in, as well as information obtained from our subscribers, trade and business organizations, and other contacts in the market sectors in which we compete, and from statistical information obtained from publicly available information, industry publications and surveys, reports from government agencies, and reports by market research firms. We confirm that, where such information is reproduced herein, such information has been accurately reproduced and that, so far as we are aware and are able to ascertain from information published by publicly available sources and other publications, no facts have been omitted that would render the reproduced information inaccurate or misleading. Industry publications, reports, and other published data generally state that the information contained therein has been obtained from sources believed to be reliable, but we cannot assure you that the information contained in these reports, and therefore the information contained in this Annual Report that is derived therefrom, is accurate or complete. Our estimates of our market position may prove to be inaccurate because of the method by which we obtain some of the data for our estimates or because this information cannot always be verified with complete certainty due to the limits on the availability and reliability of raw data, the voluntary nature of the data gathering process, and other limitations and uncertainties. As a result, although we believe our sources are reliable, we have not independently verified the information and cannot guarantee its accuracy and completeness. CAUTIONARY NOTE REGARDING FORWARD-L

RISK FACTORS

RISK FACTORS Our business is subject to numerous risks and uncertainties, including those highlighted in the section entitled "Risk Factors" in this Annual Report, that represent challenges that we face in connection with the successful implementation of our strategy and the growth of our business. In particular, the following considerations, among others, may offset our competitive strengths, or have a negative effect on our business strategy, which could cause a decline in the price of shares of our Common Stock or Warrants and result in a loss of all or a portion of your investment: We are a clinical stage biotechnology company and expect to incur significant losses for the foreseeable future and may never achieve or maintain profitability. Our ability to continue as a going concern requires that we obtain sufficient funding to finance our operations. Our current or potential future product candidates may not demonstrate the safety, purity, or efficacy necessary to become approvable or commercially viable. Although we intend to explore other therapeutic opportunities in addition to the product candidates we are currently pursuing, we may fail to identify viable new product candidates for clinical development, which could materially harm our business. Clinical development includes a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. We rely on third parties to conduct our preclinical studies, and plan to rely on third parties to conduct clinical trials, and those third parties may not perform satisfactorily. If third parties on which we intend to rely to conduct certain preclinical and clinical studies do not perform as contractually required, fail to satisfy regulatory or legal requirements or miss expected deadlines, our development program could be delayed or unsuccessful, and we may not be able to obtain regulatory approval for or commercialize our prod

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing